List of Biologics Companies in Finland - 7

Aplagon is a clinical stage biopharmaceutical company developing first-in-class therapeutics for thromboinflammatory diseases. These include thrombotic, inflammatory and fibrotic conditions. Aplagon was founded in 2009 and is based on the pioneering research performed by Prof. Riitta Lassila and associates at Wihuri Research Institute in Helsinki, Finland.

Desentum is a clinical-stage, research-oriented biopharmaceutical company specialized in developing novel types of allergy immunotherapy products (aka allergy vaccines) that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. We have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, we have made discoveries that allow for improved design of vaccines against common types of allergies. Our goal is to provide long-term relief from allergic symptoms with only a few months of treatment, as well as reduce the social and economic burden allergies cause to both individuals and society.

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. Its lead program is bexmarilimab, its investigative precision immunotherapy in Phase I/II development as a novel macrophage checkpoint immunotherapy for patients with hematological malignancies. Bexmarilimab is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Faron is based in Turku, Finland and Boston, Massachusetts. Faron is listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market ("Nasdaq First North") under ticker FARON.

Scientific Excellence for IVD. With over 30 years of experience Hytest offers antibodies and antigens for improved patient outcomes in such areas as cardiac markers, infectious, neuroscience and autoimmune disease reagents.

Rokote Laboratories Finland Oy is a Finnish vaccine development company. We are developing the Finnish COVID-19 vaccine.

TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses. Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies. TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2). Multiple Phase I clinical trials are ongoing. For contact: BD (at) tiltbio.com

Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients.